International
The Morning Science

What science found today

‹
 

Research

CD19 CAR T cell therapy alters disease-associated immune signatures in multiple sclerosis

Cell · By Felix Fischbach, Lena Kristina Pfeffer, Jan Broder Engler, Tradite Neziraj, Johanna Richter, Neda Sattarnezhad, Kristina Berve, Anne-Catherine Lecourt, Felix Schlicht, Franz F. Konen, Jana K. Sonner, Paul Saary, Anne Willing, Stefanie Reinhardt, Nina Meurs, Vanessa Vieira, Anita Badbaran, Carolina Berger, Dominic Borie, Johan Seibel, Jens Fiehler, Martin Daumer, Thomas Skripuletz, Jens Kuhle, Francis Ayuk, Christoph Heesen, Nicolaus Kröger, Boris Fehse, Tobias V. Lanz, Anne-Katrin Pröbstel & Manuel A. Friese ·

The Brief

  • A preliminary case series of five people with multiple sclerosis received CD19 CAR T cell therapy.
  • CAR T cells expanded in the cerebrospinal fluid (CSF) of these individuals.
  • CSF disease biomarkers showed sustained reductions after treatment.

Why it matters

The results suggest CD19 CAR T cell therapy can reach and alter immune activity in the central nervous system in multiple sclerosis, but the evidence comes from only five people and is preliminary.

Who’s affected

  • researchers and clinicians working on multiple sclerosis
  • immunotherapy and cell therapy researchers

In a preliminary case series of five individuals with multiple sclerosis, CD19 CAR T cell therapy is associated with the expansion of CAR T cells in the CSF and sustained reductions in CSF disease biomarkers, providing preliminary evidence for compartment-specific…

Timeline

  1. Study published in Cell describing CD19 CAR T cell effects in five people with multiple sclerosis

  2. cell.com

    CD19 CAR T cell therapy alters disease-associated immune signatures in multiple sclerosis

How do you feel about this?

0 Comments

    CD19 CAR T cell therapy alters disease-associated immune signatures in multiple sclerosis – The Morning Science